<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919554</url>
  </required_header>
  <id_info>
    <org_study_id>VO73.13</org_study_id>
    <nct_id>NCT01919554</nct_id>
  </id_info>
  <brief_title>Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents</brief_title>
  <official_title>Investigation of the Safety and Tolerability of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents With House Dust Mite-associated Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stallergenes Greer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stallergenes Greer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of different doses of
      sublingual tablets of house dust mite (HDM) allergen extracts in adolescents with house dust
      mite-associated allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability evaluated on treatment emergent adverse events</measure>
    <time_frame>10 dosing treatment days</time_frame>
    <description>Safety, tolerability evaluated on treatment adverse events and safety laboratory testings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent Serious Adverse Events</measure>
    <time_frame>10 dosing treatment days</time_frame>
    <description>Treatment emergent Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events leading to study withdrawal</measure>
    <time_frame>10 dosing treatment days</time_frame>
    <description>Incidence of adverse events leading to study withdrawal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry parameters</measure>
    <time_frame>10 dosing treatment days</time_frame>
    <description>Change in spirometry parameters between selection visit and last treatment day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety laboratory testings</measure>
    <time_frame>10 dosing treatment days</time_frame>
    <description>Change in safety laboratory testing values between selection visit and last treatment day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 lead ECG parameters</measure>
    <time_frame>10 dosing treatment days</time_frame>
    <description>Change in ECG parameters between selection visit and last treatment day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>House Dust Mite Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Placebo Sub Lingual Immunotherapy Tablets (SLIT)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets Matching the HDM allergen extract Sub Lingual Immunotherapy Tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLIT of HDM allergen extracts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual Immunotherapy Tablets of House Dust Mite allergen extracts</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SLIT tablets of HDM allergen extracts</intervention_name>
    <arm_group_label>Placebo Sub Lingual Immunotherapy Tablets (SLIT)</arm_group_label>
    <arm_group_label>SLIT of HDM allergen extracts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent from patient and parent(s)/legal representative.

          -  Male or female patient from 12 to 17 years.

          -  Diagnosed rhinitis with medical history consistent with HDM-induced allergic rhinitis
             for at least 1 year before visit 1

          -  Positive Skin Prick Test to House Dust Mites(HDM)and HDM-specific IgE serum value â‰¥
             0.7 kUnit/L.

          -  Concommittant controlled asthma allowed up to GINA 1 or 2 treatment step

          -  Spirometry with best FEV1 &gt; 80% of predicted FEV1.

        Exclusion Criteria:

          -  Patient with a nasal or oral disease that could interfere with the safety assessments

          -  Patient has undergone recent nasal surgery

          -  Patient with asthma receiving therapy consistent with GINA (Global INitiative for
             Asthama) treatment step 3, 4, or 5.

          -  Patient with partially controlled or uncontrolled asthma

          -  Patient with a past or current disease, which as judged by the Investigator, may
             affect the patient's participation in or the outcome of this study.

          -  Female patient pregnant or breast-feeding/lactating.

          -  Female patient of childbearing potential planning a pregnancy during this trial or not
             using a medically accepted contraceptive method.

          -  Patient treated with beta-blockers, tricyclic antidepressants or monoamine oxidase
             inhibitors (MAOIs).

          -  Patient who received allergy specific immunotherapy for house dust mites for more than
             1 month in the 5 years before screening or who is currently receiving immunotherapy
             with any allergen.

          -  patient with a history of anaphylaxis

          -  patient having participated in any clinical study within the 12 weeks before visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piyush Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inflamax Research Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inflamax Research Inc.</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2013</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>House Dust Mite Allergic Rhinitis</keyword>
  <keyword>Phase I</keyword>
  <keyword>House Dust Mite Allergen Extract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

